Sugi Predict

Sugi Predict / Targets / GUCY1A1

GUCY1A1

Guanylate cyclase soluble subunit alpha-1 (GC · Q02108 · GUCY1A1 on Sugi Atlas →

23,733 patent compounds predicted against GUCY1A1, 13,239 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL253278) 0.85 20/20
SCHEMBL2447914 SCHEMBL2447914 0.82 20/20
SCHEMBL250991 SCHEMBL250991 0.79 20/20
SCHEMBL252290 SCHEMBL252290 0.78 20/20
SCHEMBL2445889 SCHEMBL2445889 0.71 20/20
SCHEMBL2441721 SCHEMBL2441721 0.70 20/20
SCHEMBL2436846 SCHEMBL2436846 0.69 20/20
SCHEMBL253803 SCHEMBL253803 0.67 20/20
SCHEMBL2441717 SCHEMBL2441717 0.66 20/20
SCHEMBL253844 SCHEMBL253844 0.66 20/20
SCHEMBL254496 SCHEMBL254496 0.65 20/20
SCHEMBL2445297 SCHEMBL2445297 0.65 20/20
SCHEMBL2445626 SCHEMBL2445626 0.65 20/20
SCHEMBL2445293 SCHEMBL2445293 0.64 20/20
SCHEMBL252384 SCHEMBL252384 0.59 20/20
SCHEMBL211585 SCHEMBL211585 0.59 20/20
SCHEMBL253217 SCHEMBL253217 0.59 20/20
SCHEMBL1784657 SCHEMBL1784657 0.56 20/20
SCHEMBL1784660 SCHEMBL1784660 0.56 20/20
SCHEMBL251237 SCHEMBL251237 0.54 20/20

Clinical trials — most relevant to GUCY1A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation PHASE4COMPLETED
Vericiguat and Reverse Remodeling Indices in Heart Failure PHASE4RECRUITING
Impact of Vericiguat on Hemodynamics of Heart Failure PHASE4ACTIVE_NOT_RECRUITING
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
Methylene Blue and Microcirculation in Septic Shock PHASE3UNKNOWN
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease PHASE2COMPLETED
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE PHASE2UNKNOWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension PHASE2COMPLETED
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers PHASE2COMPLETED
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH PHASE2COMPLETED
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD PHASE2RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) PHASE2NOT_YET_RECRUITING
Vascular Effects of Endothelium-Derived Versus Hemoglobin-Transported Nitric Oxide in Healthy Subjects PHASE1COMPLETED
Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers PHASE1COMPLETED
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers PHASE1COMPLETED
: Vascular Function in Health and Disease PHASE1RECRUITING
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL EARLY_PHASE1UNKNOWN
The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting. nanUNKNOWN
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
OrthoCor Advanced Trial for Knee Osteoarthritis nanCOMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a GUCY1A1 binder may also engage these)

ProteinNameSimilarity
P19687 — 1.000 P19687 →
Q4ZHS0 — 1.000 Q4ZHS0 →
Q9ERL9 — 1.000 Q9ERL9 →
P19686 — 1.000 P19686 →
GUCY1A2 Guanylate cyclase soluble subunit alpha-2 (GC 0.996 landscape →
Q9WVI4 — 0.992 Q9WVI4 →
Q6DNF7 — 0.991 Q6DNF7 →
P92006 — 0.988 P92006 →
Q07093 — 0.988 Q07093 →
P22717 — 0.987 P22717 →
Q6DNF3 — 0.986 Q6DNF3 →
P70600 — 0.986 P70600 →
Q86YR7 — 0.985 Q86YR7 →
Q008S8 — 0.985 Q008S8 →
PTK2B Protein-tyrosine kinase 2-beta 0.985 landscape →
B0R0W9 — 0.985 B0R0W9 →
Q80TL1 — 0.985 Q80TL1 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.984 landscape →
Q61586 — 0.984 Q61586 →
Q63ZR5 — 0.984 Q63ZR5 →
Q63406 — 0.984 Q63406 →
O15068 — 0.984 O15068 →
Q8K337 — 0.984 Q8K337 →
Q6TNR1 — 0.984 Q6TNR1 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.984 landscape →
GUCY1B2 Guanylate cyclase soluble subunit beta-2 (GCS 0.984 landscape →
Q64096 — 0.983 Q64096 →
P10911 — 0.983 P10911 →
Q80YE7 — 0.983 Q80YE7 →
Q66K14 — 0.983 Q66K14 →